Definium Therapeutics (DFTX) Current Assets (2020 - 2026)

Definium Therapeutics (DFTX) has reported Current Assets for 7 consecutive years, with $380.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 71.66% year-over-year to $380.6 million; the TTM figure through Mar 2026 stood at $380.6 million (up 71.66% YoY), while the FY2025 annual figure was $419.3 million, up 48.9% from the prior year.
• Current Assets fell to $380.6 million in Q1 2026 per DFTX's latest filing, from $419.3 million in the prior quarter.
• Across five years, Current Assets topped out at $419.3 million in Q4 2025 and bottomed at $103.9 million in Q4 2023.
• Historically, Current Assets has averaged $207.2 million across 5 years, with a median of $189.1 million in 2025.
• Annual changes were most pronounced in 2023 — Current Assets retreated 28.88% — and 2024, when it soared 171.12%.
• Definium Therapeutics' Current Assets stood at $146.1 million in 2022, then declined by 28.88% to $103.9 million in 2023, then jumped by 171.12% to $281.6 million in 2024, then surged by 48.9% to $419.3 million in 2025, then fell by 9.24% to $380.6 million in 2026.
• Business Quant data shows DFTX's Current Assets at $380.6 million in Q1 2026, $419.3 million in Q4 2025, and $215.8 million in Q3 2025.